These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 17045087)

  • 21. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy.
    Kirkwood JM; Tarhini AA
    J Clin Oncol; 2009 Jun; 27(16):2583-5. PubMed ID: 19364958
    [No Abstract]   [Full Text] [Related]  

  • 22. Cytokine and vaccine therapy of kidney cancer.
    Doehn C; Kausch I; Melz S; Behm A; Jocham D
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1097-111. PubMed ID: 15606336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metastatic renal cancer and patient survival as a criterion of treatment response.
    Stathopoulos GP; Koutantos J; Rigatos SK; Stathopoulos J; Batzios S; Batziou C
    Oncol Rep; 2008 Feb; 19(2):477-81. PubMed ID: 18202797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemoimmunotherapy with low dose vinorelbine and interleukin-2 in treatment of patients with metastatic renal cell carcinoma.
    Mencoboni MP; Tredici S; Varaldo M; Queirolo G; Durand F; Rebella L; Galbusera V; Pannacciulli IM; Ghio R
    Neoplasma; 2006; 53(4):333-6. PubMed ID: 16830062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment for renal cancer: are we beyond the cytokine era?
    Ramsey S; Aitchison M
    Nat Clin Pract Urol; 2006 Sep; 3(9):478-84. PubMed ID: 16964189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
    Parton M; Gore M; Eisen T
    J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Application of IL-2 and other cytokines in renal cancer.
    McDermott DF; Atkins MB
    Expert Opin Biol Ther; 2004 Apr; 4(4):455-68. PubMed ID: 15102596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Re: C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
    Ramsey S; Aitchison M
    J Urol; 2005 Dec; 174(6):2422-3. PubMed ID: 16280863
    [No Abstract]   [Full Text] [Related]  

  • 29. Targeted therapy for renal cell carcinoma: a new therapeutic paradigm.
    Shaheen PE; Bukowski RM
    Cancer Invest; 2006 Oct; 24(6):640-56. PubMed ID: 16982470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic renal cell cancer?
    Dillman RO; Barth NM; VanderMolen LA; Fong WH; Mahdavi KK; McClure SE
    Cancer Biother Radiopharm; 2011 Jun; 26(3):273-7. PubMed ID: 21711094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.
    van der Vliet HJ; Koon HB; Yue SC; Uzunparmak B; Seery V; Gavin MA; Rudensky AY; Atkins MB; Balk SP; Exley MA
    Clin Cancer Res; 2007 Apr; 13(7):2100-8. PubMed ID: 17404092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new neuroimmunotherapeutic strategy of subcutaneous low-dose interleukin-2 plus the long-acting opioid antagonist naltrexone in metastatic cancer patients progressing on interleukin-2 alone.
    Lissoni P; Malugani F; Bordin V; Conti A; Maestroni G; Tancini G
    Neuro Endocrinol Lett; 2002 Jun; 23(3):255-8. PubMed ID: 12080288
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renal cell carcinoma.
    Rathmell WK; Martz CA; Rini BI
    Curr Opin Oncol; 2007 May; 19(3):234-40. PubMed ID: 17414642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer.
    Porta C
    Expert Rev Anticancer Ther; 2006 Jan; 6(1):141-52. PubMed ID: 16375651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response of papillary renal cell carcinoma in a solitary kidney to high dose interleukin therapy.
    Diner EK; Linehan M; Walther M
    Int J Urol; 2005 Nov; 12(11):996-7. PubMed ID: 16351658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer.
    Négrier S; Perol D; Ravaud A; Bay JO; Oudard S; Chabaud S; Fargeot P; Delva R; Deplanque G; Gravis G; Escudier B;
    Clin Cancer Res; 2008 Sep; 14(18):5907-12. PubMed ID: 18794104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EORTC-GU group expert opinion on metastatic renal cell cancer.
    de Reijke TM; Bellmunt J; van Poppel H; Marreaud S; Aapro M
    Eur J Cancer; 2009 Mar; 45(5):765-73. PubMed ID: 19157861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes and prognosis in advanced renal cell carcinoma.
    Galsky MD; Vogelzang NJ
    Expert Rev Anticancer Ther; 2007 Jun; 7(6):839-45. PubMed ID: 17555394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronically administered immunotherapy with low-dose IL-2 and IFN-alpha in metastatic renal cell carcinoma: a feasible option for patients with a good prognostic profile.
    Vaglio A; Alberici F; Maggiore U; Buti S; Potenzoni D; Passalacqua R; Buzio C
    Oncology; 2009; 76(1):69-76. PubMed ID: 19047813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful treatment of a patient on adrenal steroid replacement therapy with high-dose bolus interleukin-2 for metastatic renal cell carcinoma.
    Deshpande H; Dutcher JP; Novik Y; Oleksowicz L
    Cancer J Sci Am; 1999; 5(1):52-3. PubMed ID: 10188062
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.